Non-Government Partner
Bayer Global
Previous
Belgium
Next
Bangladesh
Bayer Global made a commitment to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030.
This ambitious goal can be reached not only through intensifying Bayer’s role as a strategic supplier to family planning programs but also via capacity building partnerships. The company has been supporting family planning programs by supplying a broad range of hormonal contraception methods for many years, encompassing both short-and long-acting products.
Commitments made to:
Vision
Bayer will build on its commitment to the ICPD Programme of Action.
Bayer Global Commitment Narratives
- Building a new production facility: Bayer will invest $160 million to produce Long-Acting Reversible Contraception (LARCs) in Costa Rica and Finland with carbon-neutral operations for sustainability.
- Improving traceability and supply coordination: Bayer has joined the “GlobalFPVan” initiative to improve the availability and accessibility of contraceptives. The hormonal IUD is now in the product catalogs of UNFPA and USAID.
- Reinvestment of profits: Bayer will reinvest all profits from global sales into capacity-building programs and partnerships. These initiatives will support the advancement of family planning and ensure sustainable access to contraceptives.
- Partnerships and collaborations: Bayer is partnering with “The Challenge Initiative” at Johns Hopkins University to institutionalize family planning in low-resource urban areas. They are committing $42.5 million to this initiative from 2020 to 2025. Bayer is also working with the German Red Cross to create a Family Planning Module for emergency response.
- Embracing innovation: Bayer is a member of the Equalizer Innovation Fund, which promotes innovative approaches in family planning. By participating in this initiative, Bayer demonstrates its commitment to advancing the accessibility and effectiveness of contraceptives.
- Non-hormonal contraception research: Bayer and the Bill & Melinda Gates Foundation are partnering to develop affordable contraception options for women worldwide. Bayer will leverage its expertise in women’s healthcare to identify a candidate for pre-clinical development, which will be made available at an affordable price in low- and lower-middle-income countries upon approval by health authorities.
Become an FP2030 Partner
